Clinical Trial Website Update, page-29

I understand what you are saying, it's true they could do that. 

This is taken from the quartly and business update 31 July. 

Current Phase 1b gastric study

During the quarter our established HER-Vaxx Phase 1b/2 gastric cancer studycontinued recruitment with five trial sites added in recent months. Study sites havereported no safety, toxicity or tolerability issues in treated patients. All vaccinatedpatients have developed immune responses and antibodies to HER2.On completion of patient recruitment of Phase 1b of the study, the data will be analysed,a recommended Phase 2 dose chosen, and we will report results to the market.